Latest Articles about IDIX

The Far-Off Four, 52-week Lows Held by Gurus

Sally Jones — Sat, 11 May 2013 22:42:08 Z

This week the GuruFocus 52-week low screener reveals the "Far-Off Four," meaning four stocks that are the farthest off-high: ANV Allied Nevada Gold Corp ( ANV ) is at a

Wealthtrack - Searching For Good Dividend Stocks

Canadian Value — Sat, 11 May 2013 17:14:44 Z

Learn why all dividends are not created equal. Robert Shearer, lead portfolio manager for BlackRock's Equity Dividend Fund explains why some dividends are better than others and where he is

IDIX at 52-Week Low - Gurus Cohen, Klarman Holding On

Sally Jones — Thu, 04 Apr 2013 03:05:55 Z

The GuruFocus 52-week low screener reveals that Idenix Pharmaceuticals ( IDIX ) is at a 52-week low, with a low price of $3.32 (73.7% off its $12.61 high). Two Guru investors Steven Cohen

Seth Klarman - IDIX Mega Shares and New FDA 'Breakthrough' Track

Sally Jones — Sat, 30 Mar 2013 02:25:58 Z

As of Feb. 9, 2013, Guru Seth Klarman , legendary value investor of The Baupost Group, added 49.69% to his Idenix Pharmaceuticals Inc. ( IDIX ) mega position currently at 24,740,200 shares.

Setback for Idenix Pharma - Analyst Blog

Zacks Equity Research — Fri, 29 Mar 2013 02:24:42 Z

Idenix Pharmaceuticals, Inc. ( IDIX ) recently suffered a setback when the US Patent and Trademark Office Patent Trial and Appeal Board (USPTO) issued a verdict against it in the first

Mid-Day Market Update: Markets Turn Red, Apollo Group Surges On Upbeat Results

Jake L'Ecuyer — Mon, 25 Mar 2013 21:11:57 Z

Midway through trading Monday, the Dow traded down 0.41 percent to 14,453.18 while the NASDAQ dropped 0.37 percent to 3,233.06. The S&P also fell, dropping 0.30 percent to 1,552.26.

Mid-Morning Market Update: Markets Rise On Cyprus Deal, Dollar General Posts Higher Profit

Jake L'Ecuyer — Mon, 25 Mar 2013 19:03:29 Z

Following the market opening Monday, the Dow traded up 0.31 percent to 14,556.33 while the NASDAQ gained 0.41 percent to 3,258.20. The S&P also rose, gaining 0.47 percent to 1,564.17.

Idenix Reports In-Line 4Q Loss - Analyst Blog

Zacks Equity Research — Fri, 01 Mar 2013 20:08:01 Z

Idenix Pharmaceuticals' ( IDIX ) loss of 17 cents per share in the fourth quarter of 2012 was a penny below the year-ago loss and in-line with the Zacks Consensus Estimate. The company's

Pipeline Setback for Idenix - Analyst Blog

Zacks Equity Research — Fri, 08 Feb 2013 03:10:01 Z

Idenix Pharmaceuticals, Inc. ( IDIX ) recently announced that the company has decided to discontinue its clinical development program for IDX184. IDX184 is a nucleotide polymerase

Mid-Afternoon Market Update: Markets Mixed, Herbalife Falld on FTC Attack on Fortune High Tech Marketing

Jake L'Ecuyer — Tue, 29 Jan 2013 01:22:29 Z

Toward the end of trading Monday, the Dow traded up 0.03 percent to 13,899.13 while the NASDAQ rose 0.29 percent to 3,158.63. The S&P fell however, decreasing 0.05 percent to 1,502.25.

Mid-Day Market Update: Zynga Rides Positive Social Media Sentiment, Jos. A Bank Falls on Bad Guidance

Jake L'Ecuyer — Mon, 28 Jan 2013 23:15:25 Z

Mid-way through trading Monday, the Dow traded down 0.10 percent to 13,881.13 while the NASDAQ rose 0.18 percent to 3,155.63. The S&P also fell, decreasing 0.15 percent to 1,500.25.

Seth Klarman Buys Rovi Corp, Novagold, Idenix Pharmaceuticals, Sells Hewlett-packard, Microsoft ...

GuruFocus — Wed, 14 Nov 2012 03:22:49 Z

Renowned value investor Seth Klarman just reported his third quarter portfolio. He bought into one new position, Rovi Corp ( ROVI ), and added to his positions in Novagold Resources, Inc.,

The Baupost Group's Seth Klarman Adds to Stake of Idenix Pharmaceuticals

Dianne Tordillo — Tue, 13 Nov 2012 23:24:21 Z

As of Nov. 9, Guru investor Seth Klarman of Boston-based hedge fund firm, the Baupost Group, has reported to adding to his shares of company, Idenix Phamaceuticals Inc. ( IDIX ), increasing

Mid-Day Market Update: Markets Mixed; Weatherford International Falls Further

Benzinga — Tue, 13 Nov 2012 23:09:44 Z

Midway through trading Tuesday, the Dow traded up 0.19 percent to 12,839.64 while the NASDAQ fell 0.21 percent to 2,8998.17 The S&P also rose, increasing 0.22 percent to 1,383.07. Top

Abbott Reports Encouraging HCV Data - Analyst Blog

Zacks Equity Research — Tue, 16 Oct 2012 23:51:34 Z

Abbott Laboratories ( ABT ) recently announced promising data from the phase IIb Aviator trial evaluating the combination of ABT-450/r, ABT-267, ABT-333 and ribavirin for the treatment of